Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam
Recommended Citation
Jalili A, Lebwohl M, Stein Gold LF, Andersen SB, Jensen KL, Pink AE, Segaert S, Berg P, Calzavara-Pinton PG, de la Cueva Dobao P, Thaçi D. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. Journal of the European Academy of Dermatology and Venereology : JEADV 2018; .
Document Type
Article
Publication Date
12-6-2018
Publication Title
Journal of the European Academy of Dermatology and Venereology : JEADV
Abstract
BACKGROUND: Itch is common in psoriasis, adversely affecting health-related quality of life (HRQoL) and sleep.
OBJECTIVE: We evaluated the efficacy of topical fixed-dose combination calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch, itch-related sleep loss and HRQoL versus foam vehicle.
METHODS: We pooled data from three Phase II/III trials (NCT01536886/NCT01866163/NCT02132936) of Cal/BD foam versus foam vehicle in adults with mild-severe psoriasis. For itch-related analyses, patients with baseline itch VAS >40 (range 1-100) were analysed. Outcomes included: itch VAS reduction >40, ≥70% improvement in itch (Itch70) or itch-related sleep loss, 75% improvement in modified PASI (excluding head) (mPASI75), and Dermatology Life Quality Index (DLQI) scores 0/1 through 4 weeks.
RESULTS: Of 837 patients, 800 had baseline itch VAS >0 (Cal/BD foam, n=610; foam vehicle, n=190); 484 had baseline itch VAS >40. There was no correlation between itch VAS score and mPASI at baseline (R
CONCLUSION: Compared with foam vehicle, Cal/BD foam offers more rapid and effective itch relief, with associated significant improvements in sleep and DLQI. This article is protected by copyright. All rights reserved.
PubMed ID
30520168
ePublication
ePub ahead of print
